Viking Therapeutics, Inc. aces hurdles for obesity drug VK2735 vs. Zepbound/Wegovy—tolerability, weak differentiation, and ...

For the quarter ended December, Viking is expected to report a loss per share of $0.91, compared to the loss of $0.32 reported in the corresponding quarter of 2024, ・The subcutaneous formulation of ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best US stocks to buy under $50. On January 12, Viking Therapeutics, ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Both companies may succeed in this industry.

If you are wondering whether Viking Therapeutics is attractively priced or already fully valued, this article walks through what the current numbers are saying about the stock. The share price has ...

We expect investors to focus on Viking Therapeutics’ VKTX progress with the development of its lead candidate, VK2735, a dual ...

What Viking Therapeutics stock’s recent moves tell you Viking Therapeutics (VKTX) shares closed at US$34.09, with the stock showing a 2.1% gain over the past day and a 6.9% rise over the past week, ...

Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options begin trading this week, for the May 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in General Motors Co (Symbol: GM), where a total of 73,915 contracts have traded so far, ...